1. Home
  2. MGIC vs RZLT Comparison

MGIC vs RZLT Comparison

Compare MGIC & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGIC
  • RZLT
  • Stock Information
  • Founded
  • MGIC 1983
  • RZLT 2010
  • Country
  • MGIC Israel
  • RZLT United States
  • Employees
  • MGIC N/A
  • RZLT N/A
  • Industry
  • MGIC Computer Software: Prepackaged Software
  • RZLT Biotechnology: Pharmaceutical Preparations
  • Sector
  • MGIC Technology
  • RZLT Health Care
  • Exchange
  • MGIC Nasdaq
  • RZLT Nasdaq
  • Market Cap
  • MGIC N/A
  • RZLT 292.0M
  • IPO Year
  • MGIC 1991
  • RZLT N/A
  • Fundamental
  • Price
  • MGIC $11.89
  • RZLT $5.20
  • Analyst Decision
  • MGIC Buy
  • RZLT Strong Buy
  • Analyst Count
  • MGIC 1
  • RZLT 8
  • Target Price
  • MGIC $15.00
  • RZLT $11.63
  • AVG Volume (30 Days)
  • MGIC 44.1K
  • RZLT 377.7K
  • Earning Date
  • MGIC 11-18-2024
  • RZLT 02-11-2025
  • Dividend Yield
  • MGIC 1.70%
  • RZLT N/A
  • EPS Growth
  • MGIC N/A
  • RZLT N/A
  • EPS
  • MGIC 0.70
  • RZLT N/A
  • Revenue
  • MGIC $535,482,999.00
  • RZLT N/A
  • Revenue This Year
  • MGIC $4.29
  • RZLT N/A
  • Revenue Next Year
  • MGIC $3.39
  • RZLT N/A
  • P/E Ratio
  • MGIC $17.20
  • RZLT N/A
  • Revenue Growth
  • MGIC N/A
  • RZLT N/A
  • 52 Week Low
  • MGIC $9.38
  • RZLT $0.90
  • 52 Week High
  • MGIC $13.40
  • RZLT $6.19
  • Technical
  • Relative Strength Index (RSI)
  • MGIC 51.98
  • RZLT 55.42
  • Support Level
  • MGIC $11.51
  • RZLT $4.70
  • Resistance Level
  • MGIC $12.24
  • RZLT $5.09
  • Average True Range (ATR)
  • MGIC 0.28
  • RZLT 0.33
  • MACD
  • MGIC -0.07
  • RZLT 0.07
  • Stochastic Oscillator
  • MGIC 43.86
  • RZLT 93.63

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.

Share on Social Networks: